Aug 13, 2020 · HepG2 cells paired with CRISPR/Cas9 offer a robust model for researching hepatitis, genetic diseases, and liver cancer.

Dec 4, 2021 · In this regard, we set out to collect up-to-date information on the HepG2 cell line to assess whether the level of heterogeneity of the cell line allows in vitro biomedical studies as a model with guaranteed production and quality.

Oct 10, 2024 · Gene Knockout (KO): Precise deletion of target genes in Hep G2 aid functional research related to liver diseases and cancer. Point Mutation & Knock-In (KI): Smart-CRISPR™ enables high-efficiency homologous recombination in Hep G2 cells to introduce precise mutations or gene insertions.

The NSMAF Knockout cell line (Hep G2) is constructed based on (1) the optimal design of the Red Cotton System, (2) CRISPR-U™ technology with efficiency 10-20 times higher than traditional methods, and (3) our exclusive EZ-editor™ product series. This cell line is validated by Sanger sequencing.

HepG2 cells are widely used for analysis of Cu toxicity and apoptosis[36,37]. By using ATP7B KO cells derived from HepG2, we assessed viability of hepatic cells without interference by intrinsic ATP7B or impairment by hybrid protein sequences[31,37] reflecting …

Feb 1, 2023 · GPC3 KO cells were generated using HepG2 cells and Crispr/Cas9 gene editing with guide RNA and a PAM site near the GPC3 furin cleavage site, which resulted in a premature stop codon in exon 4 of GPC3.

Jul 30, 2024 · We established a CRBN-knockout (KO) HepG2 cell line and examined its effect on CCl 4-induced hepatocellular damage. CRBN-KO cells exhibited reduced sensitivity to CCl 4 -induced cytotoxicity, as evidenced by decreased levels of apoptosis markers, such as cleaved caspase-3, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT ...

Nov 1, 2022 · CRISPR/Cas9 technology leads to effective editing of AGXT1 gene in HepG2 cells. AGXT1 -KO cells recapitulate the main biochemical features of AGXT1 deficiency. Response to pyridoxine of common PH1-variants mirrors clinical evidence. AGXT1 -KO cells are a new model for pathogenesis studies and drug discovery.

We developed HepG2 cell models with knockouts (KOs) for three enzymes of cholesterol synthesis, each accumulating specific sterols. Surprisingly, KOs of CYP51, DHCR24, and SC5D shared only 9% of differentially expressed genes.

Jun 8, 2022 · HepG2-SHP2-KO cells showed significantly enhanced Poly(I:C)-induced IFNB1 expression compared with HepG2-WT cells (Fig. 6d). However, we observed that r-LECT2 no longer activated innate immune responses in the absence of SHP2 (Fig. 6d, e ).